Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

• Published in: Bone marrow transplantation (Basingstoke) Vol. 53; no. 2; p. 146
• Main Authors: Kansagra, A, Inwards, D J, Ansell, S M, Micallef, I N, Johnston, P B, Hogan, W J, Markovic, S N, Porrata, L F
• Format: Journal Article
• Language: English
• Published: England 01-02-2018
• Subjects: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation - methods; Humans; Killer Cells, Natural - metabolism; Lipopolysaccharide Receptors - metabolism; Lymphoma - mortality; Male; Middle Aged; Prognosis; Survival Rate; Transplantation, Autologous - methods; Young Adult
• ISSN: 1476-5365
• DOI: 10.1038/bmt.2017.225

The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14
HLA-DR
cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14
HLA-DR
ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14
HLA-DR
. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14
HLA-DR
ratio of ⩾0.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14
HLA-DR
ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14
HLA-DR
ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.